NL-OMON37076撤回3 期
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). - CHEST-2
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- Bayer
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) Signed and dated informed consent
- •2) Patients who have completed 16 weeks of treatment in the CHEST-1 trial.
排除标准
- •See page 13 of the protocol _ Paragraph 4.2.2
研究者
相似试验
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safetyand tolerability of BAY 63-2521 in different dosesPulmonary Arterial Hypertension (PAH)MedDRA version: 17.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-003610-94-DKBayer HealthCare AG462
进行中（未招募）
1 期
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63 2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-2Pulmonary Arterial Hypertension (PAH)MedDRA version: 9.1 Level: LLT Classification code 10064911 Term: Pulmonary arterial hypertensionEUCTR2008-003610-94-FRBayer HealthCare AG462
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safety and tolerability of BAY 63-2521 in different dosesPulmonary Arterial Hypertension (PAH)MedDRA version: 18.0 Level: PT Classification code 10064911 Term: Pulmonary arterial hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-003610-94-SEBayer HealthCare AG462
进行中（未招募）
不适用
ong-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). - CHEST-2Chronic Thromboembolic Pulmonary HypertentionMedDRA version: 9.1Level: LLTClassification code 10037406Term: Pulmonary hypertension secondaryEUCTR2008-003539-19-IEBayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen270
进行中（未招募）
1 期
ong-term study to collect additional information to evaluate the safety and tolerability of BAY 63-2521 in different dosesChronic Thromboembolic Pulmonary HypertensionMedDRA version: 19.0Level: LLTClassification code 10037406Term: Pulmonary hypertension secondarySystem Organ Class: 100000004855EUCTR2008-003539-19-SKBayer AG270